INOVELON, known generically as rufinamide, is a medication primarily used in the management and treatment of seizures associated with Lennox-Gastaut syndrome (LGS), a severe form of childhood-onset epilepsy. It functions by stabilizing the nerve activity in the brain, thereby reducing the occurrence of seizures. INOVELON can be prescribed to patients aged four years and older and is often used in combination with other antiepileptic drugs to achieve better seizure control. The medication comes in tablet form and as a suspension for oral administration, offering flexibility in dosing for patients. Like all antiepileptic drugs, INOVELON requires careful dosing adjustments and monitoring for side effects, which can include dizziness, fatigue, and nausea, among others. Its specific mechanism of action distinguishes it from other seizure medications, making it a valuable option in the comprehensive management of Lennox-Gastaut syndrome.